Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 14/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.51 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.43 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921402 | 0.88 | ITGAV (0.46) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL7797597 | 0.86 | ITGAV (0.51) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL3138678 | 0.85 | ITGAV (0.54) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL30336058 | 0.83 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL13833866 | 0.83 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL4718032 | 0.82 | CXCR4 (0.57) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL12807006 | 0.82 | ITGAV (0.58) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL26032494 | 0.81 | ITGAV (0.54) | ITGAVITGB3CXCR4ITGB6ITGB5 | |
| SCHEMBL21766819 | 0.81 | ITGAV (0.60) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL22893606 | 0.81 | ITGAV (0.56) | ITGAVITGB3ITGB6ITGB5ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |